Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 86.5% in August

Posted by George Bondi on Aug 26th, 2026

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 187 shares, a drop of 86.5% from the July 30th total of 1,385 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 1,011 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. SmartHarvest Portfolios LLC lifted its position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) by 26.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,543 shares of the company’s stock after buying an additional 3,232 shares during the quarter. SmartHarvest Portfolios LLC’s holdings in Molecular Partners were worth $62,000 at the end of the most recent quarter. Institutional investors and hedge funds own 26.55% of the company’s stock.

Molecular Partners Price Performance

MOLN stock traded up $0.03 during mid-day trading on Wednesday, reaching $4.41. The company had a trading volume of 1,178 shares, compared to its average volume of 4,819. The company has a market capitalization of $178.12 million, a PE ratio of -2.27 and a beta of 1.08. The firm has a 50 day moving average of $4.04 and a 200 day moving average of $4.23. Molecular Partners has a 12 month low of $3.53 and a 12 month high of $5.36.

Molecular Partners (NASDAQ:MOLN – Get Free Report) last announced its quarterly earnings results on Tuesday, August 25th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.02. Analysts anticipate that Molecular Partners will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

MOLN has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a report on Wednesday, July 8th. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Molecular Partners currently has a consensus rating of “Hold” and an average price target of $8.38.

Check Out Our Latest Stock Analysis on Molecular Partners

Molecular Partners Company Profile

(Get Free Report)

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.